AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2014

Jan 23, 2014

32418_dirs_2014-01-23_1c98b9a4-41ec-4388-993f-a8173e08bc15.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2014-01-21

Reporting Person: Dunkerley Hugh D P (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-01-21	Common Stock	A	10000	—	Acquired	10000	Direct

Footnotes

F1: The restricted shares are awarded to compensate for the efforts on behalf of the Corporation. These shares have certain vesting conditions and shall not vest on or before July 1, 2014.